Clinical trials: Hyperkinesis
ADHD
PRC-063 Classroom Study in Children (6-12 Years of Age) With ADHD
This is a randomized, double-blind, parallel group, placebo-controlled, dose optimized, phase 3 study to evaluate the safety and efficacy of PRC-063 in the treatment of ADHD in pediatric subjects between 6 to 12 years of age.
- Trial name
- NCT03172481
- Testing
- PRC-063 oral capsules
- Where
- 6 sites in United States
- Volunteers
- 156 people
- Sponsor
- Purdue Pharma, Canada
ADHD
A Novel, Non-pharmacological, Intervention for the Management of ADHD in Adolescents
This is a 2-month study in which eligible ADHD adolescents will be provided with personalized VIZO Glasses
- Trial name
- NCT05835336
- Testing
- VIZO Glasses
- Where
- Israel
- Volunteers
- 32 people
- Sponsor
- VIZO Specs Ltd
ADHD
Treatment Compliance in Children and Adolescents on ADHD Medication
The primary research objective of this observational study is to evaluate treatment compliance over one year in children and adolescents who are newly initiated on medication approved for the treatment of ADHD in a routine…
- Trial name
- COMPLY (NCT00540826)
- Testing
- Atomoxetine, stimulants (any approved ADHD medication)
- Where
- Germany
- Volunteers
- 518 people
- Sponsor
- Eli Lilly and Company
ADHD
Placebo-Controlled Comparison of Two Different Brands of Modified-Release Oral Dosage Forms Regarding Safety and Efficacy in Children With Attention Deficit Hyperactivity Disorder (ADHD) Aged 6 - 14
Currently two different brands of modified-release formulations are providing 50% immediate release beads/pellets and 50% extended release beads/pellets, resulting in a rapid onset and dual peak concentrations of plasma…
- Trial name
- NCT00254878
- Testing
- Methylphenidate hydrochloride
- Where
- Germany
- Volunteers
- 130 people
- Sponsor
- Novartis
Attention Deficit Hyperactivity Disorder
Placebo-Controlled Multi-Centre Double-Blind Trial for Adults With Extended-Release Methylphenidate for ADHD
Investigation of efficacy and tolerability of extended-release MPD in adults with ADHD, compared with a placebo, and to acquire knowledge through long-term observation of adults
- Trial name
- EMMA (NCT00619840)
- Testing
- methylphenidate hydrochloride
- Where
- Germany
- Volunteers
- 363 people
- Sponsor
- Medice Arzneimittel Pütter GmbH & Co KG
Mental Disorders
Efficacy and Safety Study of Combination of Ginkgo Extract and Ginseng Extract in Children With ADHD(Attention Deficit Hyperactivity Disorder)
This study will evaluate clinical efficacy and safety of treatment with YY-162 in children with ADHD.
- Trial name
- ADHD (NCT01536210)
- Testing
- YY-162
- Where
- 3 sites in South Korea
- Volunteers
- 144 people
- Sponsor
- Yuyu Pharma, Inc.
Attention Deficit Hyperactivity Disorder
Evaluate Long-term Safety and Efficacy of ORADUR®-Methylphenidate in Children and Adolescents With ADHD
The purpose of this study is to evaluate the long-term safety and efficacy of ORADUR®-Methylphenidate in children and adolescents with ADHD.
- Trial name
- NCT02704390
- Testing
- ORADUR®-Methylphenidate
- Where
- 3 sites in Taiwan
- Volunteers
- 64 people
- Sponsor
- Orient Pharma Co., Ltd.
ADHD
Efficacy, Safety, and Tolerability of TC-5619 in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
ADHD has been associated with persistent deficits in the efficient allocation of attention and supports the notion that regulation of the cholinergic system may improve these cognitive deficits in ADHD.
- Trial name
- NCT01124708
- Testing
- TC-5619-238
- Where
- 16 sites in United States
- Volunteers
- 134 people, healthy volunteers welcome
- Sponsor
- Targacept Inc.
ADHD
Amphetamine Extended-Release Tablets in the Treatment of Adults With ADHD
To evaluate the efficacy of AMPH ER TAB compared to placebo in adult patients with ADHD aged 18 to 60 years.
- Trial name
- NCT03834766
- Testing
- AMPH ER Tab 5, 10, 15 and 20 mg
- Where
- 3 sites in United States
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- Tris Pharma, Inc.
ADHD - Attention Deficit Disorder With Hyperactivity, ADHD - Combined Type
Multi-center, Single Blinded, RCT, Pivotal Study to Evaluate the Efficacy and Safety of DTx to Improve ADHD
Background: Attention Deficit Hyperactivity Disorder (ADHD) is a neurodevelopmental disorder characterized by inattention, hyperactivity, impulsivity, and impaired executive functioning.
- Conditions
- ADHD - Attention Deficit Disorder With Hyperactivity, ADHD - Combined Type, ADHD
- Trial name
- NCT07173439
- Testing
- Model Name: EMT-SR01;red
- Where
- South Korea
- Volunteers
- 120 people
- Sponsor
- EMOTIV
ADHD
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Children With ADHD
This study will evaluate the efficacy and safety of high doses of SPN 812 in children with ADHD
- Trial name
- NCT03247543
- Testing
- 200mg SPN-812, 400mg SPN-812
- Where
- 10 sites in United States
- Volunteers
- 313 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Attention Deficit Hyperactivity Disorder
Long-term Safety and Effectiveness of OROS Methylphenidate HCl in Children With Attention Deficit Hyperactivity Disorder
The purpose of this study is to evaluate the long-term safety and effectiveness of OROS® Methylphenidate HCl (a central nervous system stimulant) in children with attention deficit hyperactivity disorder (ADHD).
- Trial name
- NCT00269815
- Testing
- methylphenidate HCl
- Sponsor
- Alza Corporation, DE, USA
ADHD Specifically With Executive Function Impairment
Safety and Efficacy of SPD489 on Executive Function Behaviors in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
The primary objective of the study is to evaluate the efficacy of SPD489 compared to placebo on executive function (self-regulation) behaviors in adults with ADHD who report clinically significant impairment of executive function…
- Trial name
- NCT01101022
- Testing
- SPD489
- Where
- 39 sites in United States
- Volunteers
- 161 people
- Sponsor
- Shire
Attention Deficit Hyperactivity Disorder (ADHD)
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
This study is a multi-center, randomized, double-blind, placebo-controlled, phase 3 study of MDX (1400 mg daily) for 10 weeks compared with placebo in adults with ADHD.
- Trial name
- NCT02477748
- Testing
- MDX
- Where
- 38 sites in United States, Israel
- Volunteers
- 283 people, healthy volunteers welcome
- Sponsor
- Alcobra Ltd.
Attention Deficit Hyperactivity Disorder
A Study Comparing the Effect of Atomoxetine Versus Other Standard Care Therapy on the Long Term Functioning in Attention-Deficit/Hyperactivity Disorder (ADHD) Children and Adolescents
The purpose of this study is to demonstrate that atomoxetine is superior to other early standard therapy (any treatment that investigator considers is appropriate to initiate for the treatment of Attention-Deficit/Hyperactivity…
- Trial name
- ADHD LIFE (NCT00447278)
- Testing
- Atomoxetine, Other standard therapy for ADHD
- Where
- 35 sites in Belgium, France and 7 more
- Volunteers
- 399 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Hyperactivity Disorder, Attention Deficit Disorders With Hyperactivity
Study to Assess the Safety and Efficacy of NRP104 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)
The purpose of this study is to evaluate the safety and effectiveness of NRP104 administered as a daily morning dose (30, 50, and 70mg/day) compared to placebo in adults (18-55 years of age inclusive) diagnosed with moderate to…
- Conditions
- Attention Deficit Hyperactivity Disorder, Attention Deficit Disorders With Hyperactivity, Attention Deficit Hyperactivity Disorders
- Trial name
- NCT00334880
- Testing
- NRP104
- Where
- 48 sites in United States
- Volunteers
- 420 people
- Sponsor
- New River Pharmaceuticals
Attention Deficit Hyperactivity Disorder (ADHD)
Safety and Efficacy Study in Preschool Children Aged 4-5 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
The purpose of this study is to determine if an investigational treatment is effective in improving the total score on the ADHD-RS-IV Preschool Version in children 4-5 years old diagnosed with ADHD.
- Trial name
- NCT03260205
- Testing
- SPD489 (Lisdexamfetamine dimesylate), SPD489
- Where
- 48 sites in United States
- Volunteers
- 199 people
- Sponsor
- Shire
Borderline Personality Disorder, Attention Deficit Hyperactivity Disorder
A Study to Test How BI 3031185 is Tolerated by People With Borderline Personality Disorder or Attention-deficit/Hyperactivity Disorder
This study is open to adults with certain mental health conditions. The purpose of this study is to find out how a medicine called BI 3031185 is tolerated by people with certain mental health conditions.
- Trial name
- NCT07001475
- Testing
- BI 3031185
- Where
- 7 sites in Germany
- Volunteers
- 78 people
- Sponsor
- Boehringer Ingelheim
Attention Deficit Hyperactivity Disorder, ADHD
Efficacy and Safety of Methylphenidate HCl ER Capsules in Children and Adolescents With ADHD
This multi-center parallel study is designed to study the efficacy and safety of fixed doses of methylphenidate extended release (ER) capsules of four dose levels compared with a placebo group in pediatric patients with Attention…
- Trial name
- NCT01239030
- Testing
- Methylphenidate Hydrochloride Extended Release Capsules
- Where
- 16 sites in United States
- Volunteers
- 230 people
- Sponsor
- Rhodes Pharmaceuticals, L.P.
ADHD
PRC-063 Adult Laboratory Classroom Study in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
This is a randomized, double-blind, parallel group, placebo-controlled, dose optimized, phase 3 study to evaluate the safety and efficacy of PRC-063 in the treatment of ADHD in adults
- Trial name
- NCT03618030
- Testing
- PRC-063 oral capsules
- Where
- 8 sites in United States
- Volunteers
- 288 people
- Sponsor
- Purdue Pharma, Canada